Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nissui to Launch OTC Version of Epadel in Spring 2010
November 9, 2009
- Cravit's Patent Extension Rejected by IP High Court
November 9, 2009
- OTC Drugs Market Down 1% to ¥774 Bil. in 2008: Yano Research
November 9, 2009
- Generics’Share Lowest in Japan among 15 Advanced Countries
November 9, 2009
- Kenko.com to Sell OTC Drugs On-line From Singapore
November 9, 2009
- Stroke Policy Summit Stresses the Need for Law
November 9, 2009
- R&D NEWS IN BRIEF
November 9, 2009
- Osteoporosis Treatment Effective for Glycemic Control: Prof. Sugimoto
November 9, 2009
- Korosho Invites Applications for Designation as “Global Clinical Research Centers”
November 9, 2009
- Eisai Opens Regional Office in Bahrain
November 9, 2009
- JAPhMed Calls For Increases in Transparency in Research Donations
November 9, 2009
- Eiken Chemical Launches Reagents for New-Type Influenza Virus
November 9, 2009
- AZ to Apply for Vandetanib within 2009
November 9, 2009
- Terumo to Increase Focus on Relief of Cancer Pain
November 9, 2009
- Eisai Ties Up with Quintiles to Develop Anticancer Drug Candidates
November 9, 2009
- Pharm. Business Will Continue to Growth: Mr Ludwig of BD
November 9, 2009
- REGULATORY NEWS IN BRIEF
November 9, 2009
- Half-Year Business Results of Major Domestic Companies
November 9, 2009
- DSP Completes Acquisition of Sepracor Inc.
November 2, 2009
- Astellas, IBL Discontinue Development of ASK8007 as Anti-RA Drug
November 2, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…